Wei Kiong Ngo

Wei Kiong Ngo

Auto-generated profile, based on publicly available information

Wei Kiong Ngo

Tan Tock Seng Hospital

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
CTColin S Tan
Colin S Tan
WNWei Kiong Ngo
Wei Kiong Ngo
ICIsaac W Chay
Isaac W Chay
DTDominic S Ting
Dominic S Ting
SSSriniVas R Sadda
SriniVas R Sadda
Neovascular age-related macular degeneration (nAMD) is a common world-wide cause of visual loss. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents are an effective means to treat nAMD and reduce its impact on vision compared to either sham treatment or photodynamic therapy. Currently, the approved anti-VEGF drugs include ranibizumab, aflibercept and brolucizumab. In addition, bevacizumab, used as an off-label drug, and has been shown to be effective in treating nAMD. While anti-VEGF agents are effective, its limitations include the requirement for frequent, often monthly injections, and the need for long-term treatment of nAMD. These present significant burdens on the healthcare system and on the patients. In addition, reviews of patients with nAMD treated with anti-VEGF have reported deterioration of vision over time with progression of geographic atrophy. These limitations are partly addressed by exploring different treatment regimens that reduce the frequency of treatments. Newer anti-VEGF drugs have been shown in Phase III clinical trials to have injection intervals as long as 12 or even 16 weeks for a proportion of patients. There is research on newer drugs that affect other pathways, such as the angiopoietin pathway, which may impact nAMD by extending the treatment interval and reducing the burden of treatment. Other measures include the use of sustained-release implants that release the drug regularly over a period of time, and can be refilled periodically, as well as hydrogel platforms that serve to release the drug. The use of biosimilars will also serve to reduce the cost of treatment for nAMD. A new frontier of gene therapy, primarily targeting genes involved in the transduction of retinal cells to produce anti-VEGF proteins intraocularly, also opens a new avenue of therapeutic approaches that can be used for treatment. This review paper will discuss both current treatment options and the newer treatments under development.

2 October 2024 in Asia-Pacific Journal of Ophthalmology
Verified
Journal Article
Open access
WWWendy M. Wong
Wendy M. Wong
YTYih Chung Tham
Yih Chung Tham
LALauren N. Ayton
Lauren N. Ayton
ABAlexis Ceecee Britten-Jones
Alexis Ceecee Britten-Jones
TEThomas L. Edwards
Thomas L. Edwards
HCHwei Wuen Chan
Hwei Wuen Chan
The objective of this paper is to shed light on the current landscape of genotyping practices, phenotyping practices and availability of essential vision rehabilitation management for inherited retinal diseases (IRD) in the Asia-Pacific (APAC) Region. The 62-item questionnaire was distributed electronically via email. The questions covered five domains: (1) structure of the IRD service and registry/database; (2) genotyping practices; (3) genetic counselling; (4) deep phenotyping practices; (5) low-vision rehabilitation services. The survey was completed by 36 of 45 centres in twelve countries and regions in APAC. Among these centres, 42% reported managing more than 1000 patients. Notably, 39% of centres lack an IRD database or registry, and 44% of centres have tested less than one-quarter of their IRD patients. The majority of centres (67%) do not have genetic counsellors. While there was consistency in the imaging-based investigations, there was marked heterogeneity for functional testing using electrophysiology and formal perimetry. Only 34% of centres confirmed the availability of access to low-vision assistive devices. This study reveals several critical gaps in managing IRDs in the APAC region. These include the lack of IRD database/registry in one-third of centres, a substantial proportion of patients remaining genetically undiagnosed, and limited availability of genetic counsellors. The findings also underscore a need to harmonise investigations for evaluating retinal function and identify areas for improvement in the provision of low-vision rehabilitation services.

20 July 2022 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
WNWei Kiong Ngo
Wei Kiong Ngo
LJLaura A. Jenny
Laura A. Jenny
AKAngela H Kim
Angela H Kim
MKMasha Kolesnikova
Masha Kolesnikova
VGVivienne C. Greenstein
Vivienne C. Greenstein
STStephen Tsang
Stephen Tsang

1 August 2023 in Retina
Verified
Journal Article
Closed access
WNWei Kiong Ngo
Wei Kiong Ngo
YKYariv Keshet
Yariv Keshet
ASAlfredo Salcedo-Ledesma
Alfredo Salcedo-Ledesma
JWJay Ba Walia
Jay Ba Walia
GLGerardo Ledesma-Gil
Gerardo Ledesma-Gil
RSRichard F. Spaide
Richard F. Spaide
Purpose: To investigate the use of dynamic widefield scanning laser ophthalmoscopy (SLO) and B-scan ultrasonography in imaging vitreous abnormalities in patients with complaints of floaters. Methods: Twenty-one patients underwent both dynamic SLO and B-scan ultrasonography to image their vitreous abnormalities. After reviewing these videos, patients graded each imaging technique on a scale of 1 to 10, based on how closely it represented their visual perception of floaters. Results: The mean age of the patients (12 women and nine men) was 47.7 ± 18.5 years. The patients graded a median score of nine for SLO imaging (mean = 8.43) compared with a median score of 5 (mean = 4.95) for ultrasound (P = 0.001). Widefield SLO imaging demonstrated three-dimensional interconnectivity within the condensations of the formed vitreous that exhibited translational and rotational movements with eye saccades. Conclusion: Floaters are a common complaint, but it is difficult to know whether imaging findings of the vitreous correlate to what patients perceive. Widefield SLO seems to image vitreous abnormalities related to how patients perceive their own floaters better than B-scan ultrasonography. Despite the term “floaters”, the vitreous abnormalities in the videos seemed to be manifestations of a complex three-dimensional degeneration of the vitreous framework.

29 September 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ENElvine Zhong Oen Neo
Elvine Zhong Oen Neo
KLKevin Wei Onn Liang
Kevin Wei Onn Liang
ZTZhi Hong Toh
Zhi Hong Toh
ATAndrew Bee Yong Tan
Andrew Bee Yong Tan
DCDarren Mun Yoong Choy
Darren Mun Yoong Choy
WNWei Kiong Ngo
Wei Kiong Ngo
To describe the real-world efficacy and safety outcome measurements of faricimab use in treatment-resistant neovascular age-related macular degeneration (nAMD) in a cohort of Asian patients. A tertiary hospital in central Singapore serving a resident population of approximately 1.5 million. Retrospective chart review of patients with nAMD previously treated using intravitreal bevacizumab, ranibizumab or aflibercept and were switched to faricimab between August 2022 to August 2023. Patients were switched to faricimab due to either the ineffectiveness of prior anti-VEGF agents to achieve retinal dryness or inadequate treatment intervals. Only patients who had at least one follow-up visit after switching to faricimab were included in the analysis. Primary outcome measures included best-corrected visual acuity (BCVA) in ETDRS letter score and Optical Coherence Tomography (OCT) measurements including central subfield thickness (CST), presence or absence of intraretinal fluid (IRF), subretinal fluid (SRF), intraretinal cysts and subretinal hyperreflective material (SRHM). Secondary outcome measures included adverse events and treatment history such as the mean number of injections and treatment intervals. One hundred and nineteen eyes (117 patients) with a mean age of 75.6 (58–93 years) were switched to faricimab and included in the analysis. Of these, 55 (47.0%) were males. The mean number of intravitreal anti-VEGF injections received was 28.2 ± 19.5 prior to switching to faricimab. The majority of these were switched from ranibizumab (26.1%) and aflibercept (73.1%). At baseline, BCVA was 62.7 ± 19.9 letter and mean CST on OCT was 352.5 μm ± 128.5 μm. Only 11 (9.2%) eyes were dry on OCT at baseline: 39.5% had presence of IRF, 72.3% had presence of SRF, 41.2% had presence of intraretinal cysts, and 50.4% had presence of SRHM. After switching to faricimab, the eyes received a mean of 4.8 ± 2.7 faricimab injections up to the time of data cut-off. At last visit, the mean BCVA maintained at 60.3 ± 20.7 letter and mean CST reduction was − 41.6 μm (p < 0.001). Compared to baseline, 49 (41.2%) were dry on OCT: 24.4% had presence of IRF, 41.2% had presence of SRF, 29.4% had presence of intraretinal cysts, and 48.7% had presence of SRHM (all p < 0.001). No serious ocular adverse events were reported. Switching patients with nAMD to faricimab in real-world scenarios has demonstrated the ability to maintain vision while adding anatomical gains in those previously resistant to alternative anti-VEGF therapy. Faricimab is well-tolerated with no serious ocular adverse events reported.

1 July 2024 in RETINAL Cases & Brief Reports
Verified
Journal Article
Closed access
WNWei Kiong Ngo
Wei Kiong Ngo
YKYariv Keshet
Yariv Keshet
RSRichard F. Spaide
Richard F. Spaide
Purpose: To describe a patient with venous overload choroidopathy in whom venous bulbosities masqueraded as polyps and intervortex venous anastomosis mimicked a branching vascular network, giving the appearance of polypoidal choroidal vasculopathy. Methods: The patient had complete ophthalmic examination including indocyanine green angiography and optical coherence tomography. Venous bulbosities were defined on indocyanine green angiography as focal dilations in which the diameter of the dilation is two times that of the host vessel. Results: A 75-year-old woman presented with combined subretinal and subretinal pigment epithelium hemorrhages in the right eye. During indocyanine green angiography, focal nodular hyperfluorescent lesions connected to a network of vessels were observed, which looked like polyps and branching vascular network in polypoidal choroidal vasculopathy. In both eyes, the midphase angiogram had multifocal choroidal vascular hyperpermeability. There was late-phase placoid staining nasal to the nerve in the right eye. During enhanced depth imaging–optical coherence tomography evaluation, there were no retinal pigment epithelium elevations that would be expected with polyps or branching vascular network in the right eye. A double-layer sign was seen corresponding to the placoid area of staining. Diagnosis of venous overload choroidopathy and choroidal neovascularization membrane was made. She was treated with intravitreal antivascular endothelial growth factor injections for the choroidal neovascularization membrane. Conclusion: Indocyanine green angiography findings in venous overload choroidopathy may mimic polypoidal choroidal vasculopathy, but differentiation is essential because it has implications for treatment. Similar findings may have been misinterpreted in the past and may have previously contributed to conflicting clinical and histopathologic descriptions of polypoidal choroidal vasculopathy.